8-K: Humacyte Announces Third Quarter 2024 Financial Results and Provides Business Update

Humacyte reported its third quarter 2024 financial results, highlighted progress on its ATEV product, and provided an update on the FDA review process.

Summary

• Humacyte announced its financial results for the third quarter ended September 30, 2024, with no revenue reported for the quarter or the nine-month period.
• Research and development expenses were $22.9 million for the third quarter of 2024, a decrease from $23.8 million in the previous quarter but an increase from $18.6 million in the same quarter of 2023.
• General and administrative expenses increased to $7.3 million in the third quarter of 2024, up from $5.7 million in the second quarter of 2024, due to increased sales and marketing expenses.
• The company's net loss for the third quarter of 2024 was $39.2 million, compared to a net loss of $56.7 million in the second quarter of 2024, primarily due to a reduction in the non-cash remeasurement of a contingent earnout liability.
• Humacyte reported cash, cash equivalents, and restricted cash of $71 million as of September 30, 2024, with an additional $29.6 million received from stock and warrant sales after the quarter ended.
• The FDA is still reviewing the Biologics License Application (BLA) for the ATEV in vascular trauma, with no timeline provided for completion.
• Positive results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients were presented at Kidney Week 2024.
• Long-term results from the humanitarian program using the ATEV to treat vascular injuries in Ukraine were presented at a U.S. Department of Defense meeting.
• The ATEV received its third Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, specifically for advanced peripheral artery disease.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While there are positive clinical trial results and regulatory designations, the lack of revenue, increased losses, and FDA review delays temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• The ATEV demonstrated superior functional patency in a Phase 3 trial for hemodialysis access, particularly in underserved subgroups.
• Long-term results from the use of ATEV in treating vascular injuries in Ukraine showed high rates of patency and avoidance of amputation and infection.
• The ATEV received its third Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, this time for advanced peripheral artery disease.
• Humacyte completed a registered direct offering in October 2024, raising approximately $30 million.
• The company submitted an application for a New Technology Add-on Payment (NTAP) to CMS, which could provide significant reimbursement for the ATEV if approved.
• The company's cash position was strengthened by $29.6 million after the quarter end.

Negatives

• The FDA has not provided a timeline for the completion of the BLA review for the ATEV in vascular trauma.
• Humacyte reported no revenue for the third quarter of 2024 or the nine-month period.
• The company's net loss for the third quarter of 2024 was $39.2 million.
• Research and development expenses increased year-over-year to $22.9 million for the third quarter of 2024.
• General and administrative expenses increased to $7.3 million in the third quarter of 2024 due to increased sales and marketing expenses.

Risks

• The FDA review of the ATEV BLA is taking longer than expected, and there is no timeline for completion.
• The company is still in the clinical stage and has not generated any revenue.
• The company is experiencing significant net losses.
• The company's future success depends on the successful commercialization of the ATEV and other product candidates.
• The company's financial position is dependent on continued funding.

Future Outlook

The company anticipates the potential commercial launch of the ATEV in vascular trauma, pending FDA approval, and is continuing to advance its pipeline of other product candidates. The company is also preparing for potential reimbursement through the NTAP program.

Management Comments

• Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte, stated that the FDA is still reviewing the BLA for the ATEV in vascular trauma and has not provided a timeline for completion.
• Dr. Niklason also noted that the company continues to make progress with the ATEV in other investigational indications, including hemodialysis access, and with the advancement of its broader pipeline.
• Management expressed confidence in the approvability of the ATEV in treating vascular trauma based on interactions with the FDA.

Industry Context

Humacyte is operating in the regenerative medicine and biotechnology sector, focusing on bioengineered human tissues. The company's ATEV product is aimed at addressing unmet needs in vascular trauma, hemodialysis access, and peripheral artery disease. The company is competing with traditional treatments and other companies developing advanced therapies in these areas.

Comparison to Industry Standards

• Humacyte's ATEV is being compared to autologous fistulas, the current standard of care for hemodialysis access, and has shown superior functional patency in clinical trials.
• The company's focus on regenerative medicine and bioengineered tissues is in line with a growing trend in the biotechnology industry, with companies like Organogenesis and Vericel also developing advanced therapies.
• The company's RMAT designations from the FDA are a positive sign, as they are granted to therapies that have the potential to address unmet medical needs.
• The company's financial results are typical for a clinical-stage biotechnology company, with significant research and development expenses and no revenue.

Stakeholder Impact

• Shareholders may be concerned about the lack of revenue and continued losses, but encouraged by the clinical trial results and regulatory progress.
• Employees may be impacted by the company's financial performance and the progress of its product development.
• Patients may benefit from the potential approval and commercialization of the ATEV.
• The company's suppliers and creditors may be impacted by its financial performance.

Next Steps

• The company will continue to work with the FDA to complete the review of the BLA for the ATEV in vascular trauma.
• Humacyte will continue to advance its clinical trials for the ATEV in other indications, including hemodialysis access and peripheral artery disease.
• The company will await a decision from CMS on its NTAP application.
• Humacyte will continue to develop its earlier-stage pipeline, including the BioVascular Pancreas (BVP).

Key Dates

Keywords

ATEV, Vascular Trauma, Hemodialysis, RMAT, FDA, Clinical Trial, Biologics License Application, NTAP, Regenerative Medicine, Peripheral Artery Disease, BioVascular Pancreas, BVP